Preliminary results of the Phase 1 clinical trial of newly developed compounds, STI571, showed that 31 of 31 patients with chronic myeloid leukemia (CML) had blood counts return to normal. In the world of oncology, it was unheard of. It was an unexpected data processed by Alex Matter, head of the Institute of Oncology at Novartis, AG. CML was a rare form of cancer that affected a very small number of people in the world. The development of the innovative concept of STI571 was genetically targeted drug development. This event allows students to decide whether and how they will promote the development, production and distribution of the drug, taking into account these highly successful Phase 1 results. Provides detailed information about the factors that complicate the decision, including the production of a precedent in other high-profile drug treatment, and market pressures. "Hide
by Sandra J. Sucher Stacy McManus Source: Harvard Business School 23 pages. Publication date: April 15, 2003. Prod. #: 603043-PDF-ENG
Related Case Solutions & Analyses:
Revenue Recognition Exercises
Boston Automation Systems Inc.
Note on Building the Self-Sustaining Firm
Governance at Metallgesellschaft (A)
Inventory
Airbus vs. Boeing (B): The Storm Intensifies
Machinery International
The Biggest Gorilla in the Room
Latvia: Navigating the Strait of Messina
Roche’s Acquisition of Genentech
